It Takes Balls
It Takes Balls
Tony Opted for Robotic RPLND After New TC Blood Tests Spiked
Loading
/

Tony Opted for Robotic RPLND After New TC Blood Tests Spiked

In this episode of It Takes Balls, testicular cancer survivor Tony Salas shares how his cancer journey led him into one of the newest and most rapidly evolving areas of cancer surveillance: MicroRNA-371 testing and Signatera ctDNA monitoring.

Tony opens up about the symptoms and diagnosis that changed his life, including the whirlwind of appointments, surgery, and learning how quickly testicular cancer treatment decisions have to be made. But what makes his story especially unique is what came after treatment—navigating surveillance while trying to avoid chemotherapy and gain greater confidence in whether his cancer was truly gone.

Throughout the episode, Tony discusses using MicroRNA 371, an emerging blood test showing major promise in detecting active germ cell tumors, along with Signatera, a personalized circulating tumor DNA (ctDNA) test designed to monitor for residual disease and recurrence. He shares what it was like balancing traditional surveillance methods like CT scans and tumor markers with these newer technologies, and how the uncertainty of recurrence can weigh heavily on survivors mentally and emotionally.

The conversation also explores the emotional side of survivorship, including scannxiety, the fear of recurrence, and the challenge of moving forward after treatment while still feeling tied to constant monitoring. Tony speaks candidly about the importance of self-advocacy, staying informed about evolving cancer research, and finding ways to regain a sense of control during survivorship.

This episode is not only a powerful survivor story, but also an insightful look at the future of testicular cancer surveillance and personalized cancer monitoring. Whether you’re navigating a diagnosis, currently in surveillance, or interested in the latest advances in testicular cancer treatment and recurrence detection, Tony’s experience offers both hope and perspective.

Provide your feedback on the podcast:

https://www.testicularcancerawarenessfoundation.org/itbsurvey

Join The Ball Room:

https://www.testicularcancerawarenessfoundation.org/theballroom

Want to be a guest? Apply here:

https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissions

Connect with Tony:

https://www.instagram.com/tone_loc17/

https://www.facebook.com/coachtony05

Follow Testicular Cancer Awareness Foundation:

⁠https://www.testescancer.org

https://www.x.com/testescancer⁠

⁠https://www.instagram.com/testescancer

https://www.facebook.com/tca.org

Follow Steven Crocker:

https://www.instagram.com/stevencrocker

https://www.facebook.com/steven.crocker2

Theme song: No Time Like Now - Tom Willner http://www.tomwillner.com

More From Current Show

For personal trainer Michael Autore, testicular cancer was never on his radar — until a chance conversation changed...
Listen Now
When Phil Mamwell first felt sharp, shooting pains, he did what too many men do — he told...
Listen Now
Cisplatin is one of the most powerful, life-saving drugs in testicular cancer treatment — but it comes with...
Listen Now
Bray Hansel thought he was done. After a swollen left testicle led to an orchiectomy and a pathology...
Listen Now
Attend the 2026 Testicular Cancer Conference: https://www.testicularcancerawarenessfoundation.org/tcc-indianapolis-2026 At just 24, personal trainer Andrejs Lejietis was building a business...
Listen Now
Attend the 2026 Testicular Cancer Conference: https://www.testicularcancerawarenessfoundation.org/tcc-indianapolis-2026 When David Smith woke in the middle of the night with...
Listen Now
Attend the 2026 Testicular Cancer Conference: https://www.testicularcancerawarenessfoundation.org/tcc-indianapolis-2026 In this episode of It Takes Balls, Taylor Woods shares one...
Listen Now
In this episode of It Takes Balls, internationally renowned urologic oncologist Dr. Axel Heidenreich joins the podcast for...
Listen Now

Related Episodes

No related episodes found.